Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/11224
Full metadata record
DC FieldValueLanguage
dc.rights.licenserestrictedAccess-
dc.contributor.authorSimovic Markovic, Bojana-
dc.contributor.authorKanjevac, Tatjana-
dc.contributor.authorHarrell C.-
dc.contributor.authorGazdic, Marina-
dc.contributor.authorFellabaum C.-
dc.contributor.authorArsenijevic, Nebojsa-
dc.contributor.authorVolarevic, Vladislav-
dc.date.accessioned2021-04-20T17:48:28Z-
dc.date.available2021-04-20T17:48:28Z-
dc.date.issued2018-
dc.identifier.issn1550-8943-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/11224-
dc.description.abstract© 2017, Springer Science+Business Media, LLC, part of Springer Nature. Mesenchymal stem cells (MSCs) are promising resource for the therapy of inflammatory bowel diseases (IBDs) on the grounds of their differentiation capabilities and immuno-modulatory characteristics. Results of clinical studies indicate that local application of MSCs is a secure and beneficial approach for the treatment of perianal fistulas while systemic application of MSCs leads to the attenuation or aggravation of IBDs. Herein, we emphasized molecular mechanisms and approaches that should improve efficacy of MSC-based therapy of IBDs.-
dc.rightsinfo:eu-repo/semantics/restrictedAccess-
dc.sourceStem Cell Reviews and Reports-
dc.titleMolecular and Cellular Mechanisms Involved in Mesenchymal Stem Cell-Based Therapy of Inflammatory Bowel Diseases-
dc.typereview-
dc.identifier.doi10.1007/s12015-017-9789-2-
dc.identifier.scopus2-s2.0-85034848180-
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

450

Downloads(s)

12

Files in This Item:
File Description SizeFormat 
PaperMissing.pdf
  Restricted Access
29.86 kBAdobe PDFThumbnail
View/Open


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.